Search for "SEC Live Filings Digest" to find out more.
Johnson & Johnson (JNJ) reported revenues of $17.58B in its most recent financial results announcement for the third quarter fiscal 2013. The company earned $2.98B or $1.04 per share, up slightly from $2.97B and $1.05 per share a year ago. As a result of its strong performance, Johnson & Johnson raised its annual guidance from the previously established range of $5.40 to $5.47 to now between $5.44 and $5.49 per share. The company continues to trend upward thanks to its diverse portfolio of offerings, which has led to its success whereas other competitors that rely solely on a few key products are more susceptible to volatility. CEO Alex Gorsky commented that this quarter’s results demonstrate the company’s ability to achieve both near and long-term goals while continuing to grow the business.
The GAAP earnings have not increased at all. You are referring to operating earnings not bottom line earnings. Using operating earnings to calculate earnings is very misleading. They exclude some expensive they say are nonreccuring but other recur over time so the earnings are inflated. It is a huge scam and illusion. The only earnings that matter are bottom line reported earnings.